News & Events
More Neumedicines News
 
Neumedicines Inc. is a private biotechnology company developing protein therapeutics that address unmet clinical and societal needs in the areas of Oncology, Hematology and Immunology.

NMIL12-1 (recombinant human interleukin-12 or rHuIL-12), the company’s lead product in development, targets multiple pathways of hematopoiesis and innate immunity and is being developed to address a range of clinical indications.

At Neumedicines, we are committed to maximizing the scientific, clinical, and commercial potential of our product pipeline.

© 2009 Neumedicines Inc. All rights reserved.